secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2022-11-04T23:59:59+00:00
Accession:  0001193805-22-001480
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus: Janssen ends Hep B pact, Vietnam mfg deal terminated; ARCT-154 study extended
--------------------------------------------------------------------------------

- Janssen terminated Hep B collaboration; effective in 60 days; no penalties.
- Mutual termination of Vietnam COVID-19 vaccine manufacturing deals with Vinbiocare; no penalties.
- New Study Support Agreement for ARCT-154 vaccine study; payments to Vinbiocare through Q1 2025 plus royalty.
- Arcturus takes on financial responsibility for continuing clinical activities in Vietnam.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380522001480/0001193805-22-001480-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380522001480/e617791_8k-arcturus.htm
  HTML page:      https://secwatch.observer/filing/0001193805-22-001480

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer